• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/20/26 4:29:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    false --12-31 0001616543 0001616543 2026-05-20 2026-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 20, 2026

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock SENS Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    At the 2026 Annual Meeting of Stockholders held on May 20, 2026 (the “Annual Meeting”), the stockholders of Senseonics Holdings, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Restated Certificate”) to increase the authorized number of shares of the Company’s common stock from 70,000,000 to 140,000,000 shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to Certificate of Amendment to Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on May 20, 2026 and was effective as of such date.

     

    The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting, the stockholders of the Company considered six proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 6, 2026, as amended on April 9, 2026. Of the 41,795,466 shares outstanding as of the record date, 23,650,239 shares, or 56.59%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

     

    Proposal No. 1: Election of three nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

     

    Name   Votes For     Votes Withheld     Broker Non-Votes  
    Timothy T. Goodnow     10,737,689       2,223,065       10,689,485  
    Francine R. Kaufman     10,995,083       1,965,671       10,689,485  
    Sharon Larkin     10,883,177       2,077,577       10,689,485  

     

    All nominees were elected.

     

    Proposal No. 2: Approval, on an advisory basis, of the compensation paid to the Company’s Named Executive Officers, as described in the proxy statement. The votes were cast as follows:

     

        Votes For     Votes
    Against
        Abstained     Broker Non-
    Votes
     
    Approval, on an advisory basis, of the compensation paid to the named executive officers     10,358,401       2,379,720       222,633       10,689,485  

     

    Proposal No. 3: Approval of the frequency of advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows:

     

       One Year   Two Years   Three Years   Abstained    Broker Non-
    Votes
     
    Frequency of advisory votes on compensation of the Company’s named executive officers  10,790,815      160,133    994,902    1,014,904    10,689,485 

     

    Consistent with the stockholder voting results above and the recommendation of the Board of Directors of the Company as disclosed in the Company’s proxy statement for the Annual Meeting, the Company has determined to solicit a non-binding advisory vote on the compensation of the Company’s named executive officers every year until the next required stockholder vote on the frequency of such non-binding advisory vote or until the Board of Directors of the Company determines that a different frequency of such non-binding advisory vote is in the best interest of the Company’s stockholders.

     

     

     

     

    Proposal No. 4: Ratification of the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:

     

        Votes For     Votes
    Against
        Abstained  
    Ratification of appointment of KPMG LLP     21,085,578       2,185,666       378,995  

     

    Proposal No. 5: Approval of an amendment to the Company’s amended and restated certificate of incorporation to increase the authorized number of shares of common stock from 70,000,000 to 140,000,000 shares (the “Amendment”):

     

        Votes For     Votes
    Against
        Abstained  
    Approval of an amendment to the Company's amended and restated certificate of incorporation     15,735,743       6,871,884       1,042,612  

     

    Following the approval of Proposal No. 5, on May 20, 2026, the Company filed the Amendment with the Secretary of State of the State of Delaware.

     

    Proposal No. 6: Approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan:

     

        Votes For     Votes
    Against
        Abstained     Broker Non-
    Votes
     
    Approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan       10,458,422         2,307,794         194,538        10,689,485  

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit    
    Number   Description
         
    3.1   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.
         
    104   Cover Page Interactive Data (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 20, 2026 SENSEONICS HOLDINGS, INC.

     

      By: /s/ Rick Sullivan
      Name: Rick Sullivan
      Title: Chief Financial Officer

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

    GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics

    6/1/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

    Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update

    5/7/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of c

    5/4/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    SEC Form SD filed by Senseonics Holdings Inc.

    SD - Senseonics Holdings, Inc. (0001616543) (Filer)

    6/1/26 5:07:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Senseonics Holdings Inc.

    S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:51:58 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:29:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $126,134 worth of shares (22,686 units at $5.56), increasing direct ownership by 19% to 144,635 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/13/26 4:15:05 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:42:42 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:41:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:40:28 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon

    5/1/26 9:10:31 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care